Amgros 2027 Medicinal Products Framework Agreements

Summary

Amgros I/S is procuring medicines for Danish hospital pharmacies under five separate, non-exclusive framework agreement lots: axitinib 1, 3, 5 and 7 mg tablets; tivozanib 890 and 1,340 microgram capsules; sunitinib 12.5, 25 and 50 mg capsules; and pazopanib 200 and 400 mg tablets. The estimated total value is DKK 56.4 million, with a maximum total framework value of DKK 197.4 million. The ordinary purchasing period is 1 June 2027 to 31 May 2028, with options for extensions and deliveries outside that period; there is no purchase obligation.